Lack of Efficacy Ends Trial Evaluating Janssen's HIV Vaccine Candidate

A phase 3 trial evaluating an investigational HIV vaccine regimen for the prevention of HIV-1 infection will be discontinued.

Related Keywords

,Janssen Research Development ,Penny Heaton ,Global Therapeutic Area Head ,Janssen Research ,